Chong Kun Dang Pharmaceutical Corp.

KOSE:A185750 Stock Report

Market Cap: ₩1.3t

Chong Kun Dang Pharmaceutical Future Growth

Future criteria checks 0/6

Chong Kun Dang Pharmaceutical's earnings are forecast to decline at 21.8% per annum while its annual revenue is expected to grow at 1.9% per year. EPS is expected to decline by 23.1% per annum. Return on equity is forecast to be 11.4% in 3 years.

Key information

-21.8%

Earnings growth rate

-23.1%

EPS growth rate

Pharmaceuticals earnings growth36.4%
Revenue growth rate1.9%
Future return on equity11.4%
Analyst coverage

Good

Last updated29 Apr 2024

Recent future growth updates

Recent updates

Investors Don't See Light At End Of Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Tunnel

Jun 12
Investors Don't See Light At End Of Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Tunnel

Chong Kun Dang Pharmaceutical (KRX:185750) Seems To Use Debt Rather Sparingly

May 27
Chong Kun Dang Pharmaceutical (KRX:185750) Seems To Use Debt Rather Sparingly

A Look At The Fair Value Of Chong Kun Dang Pharmaceutical Corp. (KRX:185750)

Apr 09
A Look At The Fair Value Of Chong Kun Dang Pharmaceutical Corp. (KRX:185750)

Does Chong Kun Dang Pharmaceutical (KRX:185750) Have A Healthy Balance Sheet?

Apr 19
Does Chong Kun Dang Pharmaceutical (KRX:185750) Have A Healthy Balance Sheet?

Here's Why I Think Chong Kun Dang Pharmaceutical (KRX:185750) Is An Interesting Stock

Apr 05
Here's Why I Think Chong Kun Dang Pharmaceutical (KRX:185750) Is An Interesting Stock

Declining Stock and Solid Fundamentals: Is The Market Wrong About Chong Kun Dang Pharmaceutical Corp. (KRX:185750)?

Mar 09
Declining Stock and Solid Fundamentals: Is The Market Wrong About Chong Kun Dang Pharmaceutical Corp. (KRX:185750)?

Estimating The Fair Value Of Chong Kun Dang Pharmaceutical Corp. (KRX:185750)

Feb 24
Estimating The Fair Value Of Chong Kun Dang Pharmaceutical Corp. (KRX:185750)

The Chong Kun Dang Pharmaceutical (KRX:185750) Share Price Is Up 112% And Shareholders Are Boasting About It

Feb 11
The Chong Kun Dang Pharmaceutical (KRX:185750) Share Price Is Up 112% And Shareholders Are Boasting About It

Is Chong Kun Dang Pharmaceutical Corp. (KRX:185750) An Attractive Dividend Stock?

Jan 27
Is Chong Kun Dang Pharmaceutical Corp. (KRX:185750) An Attractive Dividend Stock?

Does Chong Kun Dang Pharmaceutical (KRX:185750) Have A Healthy Balance Sheet?

Jan 12
Does Chong Kun Dang Pharmaceutical (KRX:185750) Have A Healthy Balance Sheet?

With EPS Growth And More, Chong Kun Dang Pharmaceutical (KRX:185750) Is Interesting

Dec 28
With EPS Growth And More, Chong Kun Dang Pharmaceutical (KRX:185750) Is Interesting

What Kind Of Shareholders Hold The Majority In Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Shares?

Dec 09
What Kind Of Shareholders Hold The Majority In Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Shares?

Could The Market Be Wrong About Chong Kun Dang Pharmaceutical Corp. (KRX:185750) Given Its Attractive Financial Prospects?

Nov 24
Could The Market Be Wrong About Chong Kun Dang Pharmaceutical Corp. (KRX:185750) Given Its Attractive Financial Prospects?

Earnings and Revenue Growth Forecasts

KOSE:A185750 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,735,717125,000159,667179,0006
12/31/20251,644,856103,875127,513150,1569
12/31/20241,541,45096,180137,000164,9508
3/31/20241,665,726202,243249,344321,128N/A
12/31/20231,669,404212,521249,354318,160N/A
9/30/20231,561,851136,097134,793206,913N/A
6/30/20231,542,134119,04552,863125,597N/A
3/31/20231,512,15499,38151,004103,844N/A
12/31/20221,488,34580,95314,67067,734N/A
9/30/20221,453,15970,692-31,83512,119N/A
6/30/20221,411,50844,292-24,84419,113N/A
3/31/20221,373,01845,096-35,29513,964N/A
12/31/20211,343,55942,720-38,93012,904N/A
9/30/20211,318,91452,31915,26866,304N/A
6/30/20211,335,06685,11638,97887,610N/A
3/31/20211,321,55888,79249,40892,670N/A
12/31/20201,303,00691,63367,506104,324N/A
9/30/20201,263,96596,31661,95595,132N/A
6/30/20201,186,15675,88960,98992,526N/A
3/31/20201,138,68960,91648,31076,123N/A
12/31/20191,079,33853,88252,42977,291N/A
9/30/20191,046,38751,32766,18089,129N/A
6/30/20191,000,91050,37855,22275,429N/A
3/31/2019971,68850,42227,15850,953N/A
12/31/2018956,21942,39917,98842,628N/A
9/30/2018934,98243,6824,84733,677N/A
6/30/2018919,53446,68821,12748,954N/A
3/31/2018893,20445,20441,74865,370N/A
12/31/2017884,36353,807N/A81,673N/A
12/31/2016831,98640,946N/A57,786N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A185750's earnings are forecast to decline over the next 3 years (-21.8% per year).

Earnings vs Market: A185750's earnings are forecast to decline over the next 3 years (-21.8% per year).

High Growth Earnings: A185750's earnings are forecast to decline over the next 3 years.

Revenue vs Market: A185750's revenue (1.9% per year) is forecast to grow slower than the KR market (10.5% per year).

High Growth Revenue: A185750's revenue (1.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: A185750's Return on Equity is forecast to be low in 3 years time (11.4%).


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.